The estimated Net Worth of Christopher Molineaux is at least $474 Thousand dollars as of 10 November 2021. Christopher Molineaux owns over 100,000 units of Calithera Biosciences Inc stock worth over $27,859 and over the last 10 years he sold CALA stock worth over $0. In addition, he makes $446,601 as Senior Vice President - Development at Calithera Biosciences Inc.
Christopher has made over 9 trades of the Calithera Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of CALA stock worth $85,000 on 10 November 2021.
The largest trade he's ever made was buying 100,000 units of Calithera Biosciences Inc stock on 10 November 2021 worth over $85,000. On average, Christopher trades about 10,209 units every 101 days since 2015. As of 10 November 2021 he still owns at least 557,188 units of Calithera Biosciences Inc stock.
You can see the complete history of Christopher Molineaux stock trades at the bottom of the page.
Dr. Christopher J. Molineaux Ph.D. serves as Senior Vice President - Development of the Company. Dr. Molineaux joined Calithera in April 2013 and currently serves as our Senior Vice President of Development. From March 2010 to March 2013, Dr. Molineaux served as the President of INDStrat LLC, a consulting firm. From July 2004 to November 2009, Dr. Molineaux served as Vice President of Development at Proteolix, Inc. From 2000 to 2004, Dr. Molineaux served as Senior Director of Drug Development at FibroGen, Inc., a biotechnology company. From 1999 to 2000, he served as Research Manager of Toxicology at Johnson & Johnson Pharmaceutical Research and Development. From 1994 to 1999, Dr. Molineaux served as Senior Director of Pharmacology at Praecis. From 1991 to 1994, he served in staff scientist positions at Enzon Pharmaceuticals, Inc. and Merck & Co. From 1985 to 1991, Dr. Molineaux served as an Assistant Professor of Pharmacology of Mount Sinai School of Medicine in New York City. He received a B.S. in Zoology from University of Maryland, College Park, a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins University and completed his postdoctoral fellowship at the Uniformed Services University of the Health Sciences.
As the Senior Vice President - Development of Calithera Biosciences Inc, the total compensation of Christopher Molineaux at Calithera Biosciences Inc is $446,601. There are 5 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of $2,209,840.
Christopher Molineaux is 66, he's been the Senior Vice President - Development of Calithera Biosciences Inc since 2013. There are 3 older and 18 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C...., and Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
Calithera Biosciences Inc executives and other stock owners filed with the SEC include: